ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
September 07 2018 - 04:21AM
ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company
dedicated to changing lives through the creation of transformative
RNA medicines for the treatment of severe genetic rare diseases,
today announced the pricing of its previously announced
underwritten public offering of 5,750,000 ordinary shares at a
price to the public of $15.75 per share. All of the
shares are being offered by ProQR. The offering is expected
to close on September 11, 2018, subject to customary closing
conditions. In addition, ProQR has granted the underwriters a
30-day option to purchase up to 862,500 additional ordinary shares
at the public offering price, less underwriting discounts and
commissions. Gross proceeds from the offering are expected to
be approximately $90.6 million, assuming no exercise of the
underwriters’ option to purchase additional shares.Citigroup,
Evercore ISI and RBC Capital Markets are acting as joint
bookrunners for the offering. H.C. Wainwright & Co. and
Chardan are acting as co-managers for the offering. Kempen
& Co is acting as the Company’s European financial advisor in
relation to this offering.A shelf registration statement relating
to the offered ordinary shares was filed with the Securities
and Exchange Commission (SEC) on October 2, 2015, which
was declared effective on October 19, 2015. A
preliminary prospectus supplement related to the offering has been
filed with the SEC and is available on the SEC's website,
located at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may be obtained, when available, from Citigroup Global
Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone at
(800) 831-9146; Evercore ISI, Attention: Equity Capital Markets, 55
East 52nd Street, 36th Floor, New York, NY 10055, or by telephone
at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or
RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey
Street, 8th Floor, New York, NY 10281, or by telephone at (877)
822-4089, or by email at equityprospectus@rbccm.com.This press
release shall not constitute an offer to sell or a solicitation of
an offer to buy these securities nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the
creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis
10, dystrophic epidermolysis bullosa and cystic fibrosis. Based on
our unique proprietary RNA repair platform technologies we are
growing our pipeline with patients and loved ones in mind.*Since
2012*Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements are based on management’s beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, statements about the anticipated
closing of the offering of ProQR’s ordinary shares. These
forward-looking statements involve risks and uncertainties, many of
which are beyond ProQR’s control, including risk and uncertainties
related to market conditions and satisfaction of customary closing
conditions related to the offering. There can be no assurance that
ProQR will be able to complete the offering on the anticipated
terms, or at all. Applicable risks also include those that are
included in ProQR’s prospectus supplement and accompanying
prospectus filed with the SEC for the offering, including the
documents incorporated by reference therein, which include ProQR’s
Annual Report on Form 20-F for the year ended December 31, 2017,
and any subsequent SEC filings. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
ProQR Therapeutics N.V.:Smital ShahChief
Financial OfficerT: +1 415 231 6431ir@proqr.com
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Feb 2024 to Mar 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Mar 2023 to Mar 2024